INTRODUCTION
============

Torque teno viruses (TTVs) are small, non enveloped viruses, with an icosahedral capsid and a single-stranded circular DNA genome. One characteristic of TTVs is the extreme genomic heterogeneity that is highly uncommon for DNA viruses. Three virus species that infect humans have now been identified: TTV ( *Torque teno virus* ) \[ [@b1-bjmg-16-01-55] \] , TTMV ( *Torque teno mini virus* ) \[ [@b2-bjmg-16-01-55] \] and TTMDV ( *Torque teno midi virus* ) \[ [@b3-bjmg-16-01-55] \] . *Torque teno mini virus* (2.8--2.9 kb) and TTMDV (3.2 kb) have smaller genomes than the TTV genome (3.75--3.9 kb). The TTV, TTMV and TTMDV each consist of a wide repertoire of isolates with genome-wide sequence divergences of at least 50.0, 40.0 and 33.0%, respectively \[ [@b4-bjmg-16-01-55] \] . Based on genomic heterogeneity, TTVs were separated into 39 genotypes and five major genetic groups \[ [@b5-bjmg-16-01-55] , [@b6-bjmg-16-01-55] \] , and it was suggested that these viruses may exist as a swarm of closely related but different viral species \[ [@b7-bjmg-16-01-55] \] .

The sequence divergence is not evenly distributed throughout the genome. The untranslated region (UTR) is well conserved (73.0% nucleotide identity between the two highly divergent isolates TA278 and SANBAN *vs.* 57.0% for the entire genome) and contains several highly conserved sequences (with more than 90.0% identity between isolates). In contrast, the translated region is characterized by a very high degree of diversity \[ [@b8-bjmg-16-01-55] , [@b9-bjmg-16-01-55] \] .

The TTVs disease-causing potential is still under debate. Rocchi *et al.* \[ [@b10-bjmg-16-01-55] \] showed that certain variants present CpG motifs that are activators of proinflammatory cytokine production *via* toll-like receptor 9, and thus, may increase severity of inflammatory diseases. For the identification of these variants, new methods for assessing the viral diversity are needed.

Polymerase chain reaction (PCR)-based methods were used to detect the presence of TTVs DNA in biological samples. The high TTVs sequence divergence and the particularities of PCR assay used for detection (primers, genomic region amplified, protocols) \[ [@b11-bjmg-16-01-55] \] may determine preferential amplification of some TTV genotypes and, thus, can influence the prevalence rates of TTVs presented in different articles.

One of the first diagnostic assays for TTVs was based on PCR that used primers derived from the N22 region of ORF1 \[ [@b1-bjmg-16-01-55] \] . This primer set did not amplify all TTV phylogenetic groups. Subsequently, PCR techniques aimed for the conserved UTR, near the 5' end of ORF2 (Takahashi *et al.* \[ [@b12-bjmg-16-01-55] \] ) or near the 3' end of ORF3 (Leary *et al.* \[ [@b13-bjmg-16-01-55] \] ).

Methods based on analysis of changes in fluorescence intensity contribute to genome diversity analysis. One of these methods is high-resolution melting analysis (HRMA) \[ [@b14-bjmg-16-01-55] \] , which uses high data-density acquisition during melting of amplicons in the presence of intercalating dye. Because of its low-cost, speed and simplicity, this method is used for genetic discrimination of various microorganisms, including viruses \[ [@b15-bjmg-16-01-55] -- [@b18-bjmg-16-01-55] \] and bacteria \[ [@b19-bjmg-16-01-55] , [@b20-bjmg-16-01-55] \] . However, as far as we know, it has never been used for TTVs genotyping. The aim of this study was to assess if HRMA can be used for efficient and rapid detection of TTVs variants.

MATERIALS AND METHODS
=====================

Samples and DNA Extraction
--------------------------

A total of 113 healthy subjects from Bucharest, Romania, ranging in age from 19 to29 years, were selected for this study. Blood and saliva samples from 13 subjects were used for protocol optimization, whereas saliva samples ( *n* = 100) were used to estimate the TTVs prevalence. All subjects gave written informed consent to participate in this study according to the Helsinki Declaration of 1975, as revised in 1983, concerning the ethical principles for medical research involving human subjects.

DNA was extracted from each blood sample using four different commercial kits (recommended for DNA extraction from eukaryotic cells): two spin-column-based protocols, AxyPrep™ Blood Genomic DNA Miniprep Kit (Axygen, Union City, CA, USA) and Ron's Blood DNA Mini Kit (Bioron, Ludwigshafen, Germany), and two protocols without spin-column. Wizard® Genomic DNA Purification Kit (Promega, Madison, WI, USA), Pronto® DNA Extraction Kit (Pronto Diagnostics, Rehovot, Israel). The DNA was extracted according to the manufacturer's instructions from 250 μL of blood. A one-tube purification method, OTP reagent (Bioron), was used for DNA extraction from saliva.

Polymerase Chain Reaction
-------------------------

The detection of the three TTVs was realized using a two-step heminested-PCR protocol as described by Ninomiya *et al.* \[ [@b4-bjmg-16-01-55] \] . Each DNA sample was PCR amplified using three DNA-polymerases: GoTaq® DNA Polymerase (Promega), Immolase™ DNA Polymerase (Bioline, Luckenwalde, Germany), and Dry PCR Master Mix (blue-stain) (Bioron).

For the first step, the amplification reaction was carried out in a total volume of 15 μL containing 1 × PCR buffer solution, 1.5 mmol/L MgCl ~2~ , 100 μmol/L dNTP mix, 0.5 μmol/L of each primer, 0.6 units of DNA-polymerase and 1.5 μL of genomic DNA extract. The second step consisted of three different reactions for the specific amplification of the viral species. For the second step, 1 μL of amplicon from the first round of PCR was used as a template. The amplification programs and primers can be found in [Table 1](#t1-bjmg-16-01-55){ref-type="table"} . The amplicons of the second PCR were resolved by 2.0% (w/v) agarose gel and were electrophoresed at 5 V/cm for 20 min. The gel was visualized under UV light after ethidium bromide staining.

High-Resolution Melting Analysis
--------------------------------

The samples co-infected with all three TTVs were further analyzed by HRMA using three commercial kits and two different fluorescent dyes: SensiMix® with EvaGreen® (Bioline), Invitek SYBR Green Master Mix (Invitek, Berlin, Germany) and Maxima® SYBR Green qPCR (Fermentas, Glen Burnie, MD, USA). The amplification reaction was carried out in a total volume of 20 μL and used 2 μL of second-round amplicons as template DNA. High-resolution melting analysis was performed in a Rotor-Gene 6000 series instrument (Corbett Research, Sydney, NSW, Australia) using software version 1.7.

Melting curves were generated by increasing the temperature from 65°C to 90°C ramping by 0.1 degrees per step, with a gap of 2 seconds between steps. For the HRMA normalization regions of 75--77°C and 88--90°C were applied.

RESULTS
=======

The prevalence of TTV, TTMDV and TTMV in saliva samples was 71.0, 31.0 and 54.0%, respectively. There were no qualitative differences in the genotyping results obtained for the same sample extracted with four commercial kits and amplified with three different DNA polymerases. The distribution of TTVs did not differ in blood and saliva samples ( [Table 2](#t2-bjmg-16-01-55){ref-type="table"} ).

Ten samples with triple coinfection were selected for the HRMA using SensiMix®, SYBR Green Master Mix and Maxima® SYBR Green qPCR commercial kits ( [Figure 1a](#f1-bjmg-16-01-55){ref-type="fig"} , [Figure 2](#f2-bjmg-16-01-55){ref-type="fig"} and [Figure 3](#f3-bjmg-16-01-55){ref-type="fig"} ). Prior to HRMA, amplicons were verified by gel electrophoresis ( [Figure 4](#f4-bjmg-16-01-55){ref-type="fig"} ).

The three major melting curve patterns corresponding to TTV, TTMDV and TTMV can be easily distinguished regardless of the kit used, although they present slightly different aspects. The melting curve patterns were similar when samples were retested under the same conditions.

DISCUSSION
==========

Torque teno viruses have several characteristics ( *e.g.,* genomic heterogeneity, great number of isolates, high prevalence) that play an important role in the way their analysis must be approached. A wide range of TTV prevalence has been described worldwide. Depending on the identification method used, TTV prevalence may vary from 46.0--62.0% in Brazil \[ [@b21-bjmg-16-01-55] , [@b22-bjmg-16-01-55] \] to 94.0% in Russia \[ [@b23-bjmg-16-01-55] \] . For TTMV, prevalence ranges between 48.0% in Norway \[ [@b24-bjmg-16-01-55] \] and 67.0--72.0% in Brazil \[ [@b21-bjmg-16-01-55] , [@b22-bjmg-16-01-55] \] , and TTMDV occurs in at least 40.0% of the general population \[ [@b25-bjmg-16-01-55] \] . Our results are in accordance with prevalence values reported for TTVs in other populations, except for TTMDV, which has a lower prevalence in subjects selected for this study (31.0%).

Analyzing such heterogeneous genomes represents a challenge. The high sequence variation of the genomes, along with high percentage of cytosine and guanine, make primer design difficult. The heminested PCR assay designed by Ninomiya *et al.* \[ [@b4-bjmg-16-01-55] \] amplifies at least 49 TTV isolates, 20 TTMDV isolates, and 13 TTMV isolates.

The 10 melting curve patterns on the HRMA suggest that different viral isolates may be present in our cohort, or individuals may be coinfected with several isolates. These may explain the shift of the melting curve for TTMDV and TTMV samples marked in [Figure 1](#f1-bjmg-16-01-55){ref-type="fig"} and [Figure 3](#f3-bjmg-16-01-55){ref-type="fig"} .

The melting curve aspect is influenced by the length, percentage of cytosine and guanine (%GC) and melting point (T ~m~ ) of the amplification products. The %GC and T ~m~ were calculated *in silico* for amplicons produced by five isolates of each virus ( [Table 2](#t2-bjmg-16-01-55){ref-type="table"} ).

The differences between TTV and TTMDV amplicons are minimal, and an accurate discrimination is difficult. Moreover, we have run a folding simulation for each of the amplicons using Quickfold \[ [@b26-bjmg-16-01-55] \] at 65°C (the temperature in the beginning of HRMA) and observed that each amplicon forms slightly different secondary structures when denatured. This influences the melting curve pattern. Subsequent to HRMA, the resulting amplicons were verified by gel electrophoresis and no differences were observed ( [Figure 4](#f4-bjmg-16-01-55){ref-type="fig"} ).

Another component of the HRMA that influences the curve patterns is the fluorescent dye. There are various types of double-stranded DNA (dsDNA) intercalating dyes with different properties. For HRMA, the dye must provide detailed information on the melting behavior of an amplified target. Ideally, the dye should not bind preferentially to pyrimidines or purines, change the T ~m~ of the amplicon, or inhibit DNA amplification.

There are two main types of dyes: saturating and non saturating dyes. SYBR® Green I is a non saturating dsDNA intercalating dye and is not usually recommended for high-resolution melt applications because at high concentrations, SYBR® Green I inhibits the DNA polymerase. At low concentrations SYBR® Green I is able to redistribute from the melted regions back to the regions of dsDNA, which results in poor base-difference discrimination \[ [@b27-bjmg-16-01-55] \] .

EvaGreen® is a special kind of saturating dye, so - called "release-on-demand." For this dye, the fluorescence is quenched when unbound to DNA, this allows the use of non saturating dye concentrations, thus ensuring no PCR inhibition. EvaGreen® improves the resolution and accuracy of HRMA by increased fluorescence and lack of redistribution during melting \[ [@b28-bjmg-16-01-55] \] . Farrar *et al.* \[ [@b29-bjmg-16-01-55] \] showed that EvaGreen® is more suitable than SYBR® Green I for HRMA.

Our results show that the best discrimination is obtained using EvaGreen® ( [Figure 1](#f1-bjmg-16-01-55){ref-type="fig"} *vs.* [Figures 2](#f2-bjmg-16-01-55){ref-type="fig"} and [3](#f3-bjmg-16-01-55){ref-type="fig"} ). The differences between the curve patterns obtained with SYBR® Green I may be due to the DNA-polymerase activity \[SYBR Green Master Mix ( [Figure 2](#f2-bjmg-16-01-55){ref-type="fig"} ) *vs.* Maxima® SYBR Green qPCR ( [Figure 3](#f3-bjmg-16-01-55){ref-type="fig"} )\] and/or dye concentration in the master mixes used for this study.

As with any technique, HRMA analysis has its limitations. Fluorescent dyes used in HRMA lack sequence specificity and can bind to any dsDNA, including non targets such as primer dimmers and non specific products, which will bias the results of melting analysis \[ [@b28-bjmg-16-01-55] \] . In addition, all the PCR components are present at the time of melting analysis and may have a great impact on the melting curve shape and position \[ [@b30-bjmg-16-01-55] \] .

The amplicons corresponding to TTV, TTMDV, and TTMV obtained in the assay we used have different lengths ( [Table 3](#t3-bjmg-16-01-55){ref-type="table"} ). The %GC and also GC distribution in relation to the ends/center of amplicons differ due to genomic heterogeneity. These aspects influence the melting curves' aspect as well.

Despite these limitations, HRMA is a sensitive method and provides more information on the amplification products, such as sequence-dependent shape of the melting curve and T ~m~ , enabling discrimination of products with same length but different sequence \[ [@b31-bjmg-16-01-55] \] .

Our results showed that HRMA is a rapid method of detecting human TTVs (HRMA takes approximately 20 min. after second round amplicons are obtained) compared to the classical PCR-electrophoresis method, which is more time-consuming (gel preparation, running and staining). High-resolution melting analysis provides additional information regarding amplification products (T ~m~ , melting curve shape) compared to classic PCR methods followed by gel electrophoresis, which indicate only the presence or absence of the target sequence.

In conclusion, due to the advantages of this technique, HRMA is a rapid and accurate method for detecting TTVs. Developing new and more sensitive HRMA assays may lead to easy and accurate detection of TTV isolates.
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###### 

Amplification conditions and primers \[ [@b4-bjmg-16-01-55] \] for heminested polymerase chain reaction.

  **First Round of Polymerase Chain Reaction**                              
  ----------------------------------------------------- --------- --------- ---------
  1 × [^a^](#tfn1-bjmg-16-01-55){ref-type="table-fn"}   10 min.             
  1 ×                                                   2 min.              
  2 ×                                                   2 min.    30 sec.   30 sec.
  35 ×                                                  35 sec.   30 sec.   30 sec.
  1 ×                                                                       1 min.

  **Second Round of Polymerase Chain Reaction**                             
  ----------------------------------------------------- --------- --------- ---------
  1 × [^a^](#tfn1-bjmg-16-01-55){ref-type="table-fn"}   10 min.             
  1 ×                                                   2 min.    30 sec.   30 sec.
  27 ×                                                  30 sec.   30 sec.   30 sec.
  1 ×                                                                       1 min.

  **Primers**                                          
  ------------- ------------------------ ------------- --------------------
  Primer Code   PCR Round                Specificity   Forward of Reverse
  NG779         first and second (TTV)   general       F
  NG780         first and second (TTV)   general       F
  NG781         first                    general       R
  NG782         first                    general       R
  NG785         second                   TTV           R
  NG795         second                   TTMDV         F
  NG796         second                   TTMDV         R
  NG791         second                   TTMV          R
  NG792         second                   TTMV          F
  NG793         second                   TTMV          F
  NG794         second                   TTMV          F

Additional step for hot-start enzymes (Immolate™ DNA polymerase, Bioline; and Dry PCR Master Mix, Bioron).

###### 

Torque teno virus genotyping results obtained with three DNA polymerases from blood and saliva DNA extracted with different commercial kits. (A: GoTaq® DNA Polymerase, Promega; B: Immolate™ DNA Polymerase, Bioline; C: Dry PCR Master Mix, Bioron)

        **DNA Extraction Kit**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ----- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------- ------- ------- ------------------------------------------------------- ------------------------------------------------------- ------- ------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------
        **DNA Polymerase**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  *n*   A                                                       B                                                       C                                                       A                                                       B                                                       C                                                       A       B       C       A                                                       B                                                       C       A                                                       B                                                       C
  1     \[−\]                                                   \[−\]                                                   \[−\]                                                   \[−\]                                                   \[−\]                                                   \[−\]                                                   \[−\]   \[−\]   \[−\]   \[−\]                                                   \[−\]                                                   \[−\]   \[−\]                                                   \[−\]                                                   \[−\]
  2     \[+\]                                                   \[+\]                                                   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\]                                                   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\]   \[+\]   \[+\]   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\]   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}
  3     \[+\]                                                   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]   \[+\]   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]                                                   \[+\]                                                   \[+\]
  4     \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]   \[+\]   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]                                                   \[+\]                                                   \[+\]
  5     \[+\]                                                   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\]                                                   \[+\]                                                   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\]                                                   \[+\]   \[+\]   \[+\]   \[+\]                                                   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\]   \[+\]                                                   \[+\]                                                   \[+\]
  6     \[+\]                                                   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]   \[+\]   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]                                                   \[+\]                                                   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}
  7     \[+\]                                                   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]   \[+\]   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]                                                   \[+\]                                                   \[+\]
  8     \[−\]                                                   \[−\]                                                   \[−\]                                                   \[−\]                                                   \[−\]                                                   \[−\]                                                   \[−\]   \[−\]   \[−\]   \[−\]                                                   \[−\]                                                   \[−\]   \[−\]                                                   \[−\]                                                   \[−\]
  9     \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]   \[+\]   \[+\]                                                   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\]   \[+\]                                                   \[+\]                                                   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}
  10    \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]   \[+\]   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]                                                   \[+\]                                                   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}
  11    \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]   \[+\]   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]                                                   \[+\]                                                   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}
  12    \[+\]                                                   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]   \[+\]   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]                                                   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\]
  13    \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]   \[+\]   \[+\]                                                   \[+\]                                                   \[+\]   \[+\]                                                   \[+\] [^a^](#tfn2-bjmg-16-01-55){ref-type="table-fn"}   \[+\]

Indicates a weaker signal in agarose gel.

###### 

Amplicon properties for five isolates of the torque teno virus, torque teno midi virus and torque teno mini virus.

  **Isolate**           **Length (bp)**   **%GC**   **T ~m~**
  --------------------- ----------------- --------- -----------
  *Torque Teno Virus*                               
  TA278                 114               63        85
  JA9                   114               63        85
  JA1                   114               65        86
  JA4                   114               65        86
  JA20                  114               66        86

  -------------------------- ---- ---- ----
  *Torque Teno Midi Virus*             
  MDJHem2                    88   67   85
  SAV2                       88   68   85
  MD2-032                    88   69   86
  MD1-073                    88   70   86
  SAV1                       88   70   86
  -------------------------- ---- ---- ----

  -------------------------- ---- ---- ----
  *Torque Teno Mini Virus*             
  CBD203                     70   54   77
  CLC062                     72   58   79
  CBD279                     72   60   80
  CBD231                     72   61   80
  CLC138                     72   61   81
  -------------------------- ---- ---- ----
